Arsenal Bio Just Torched Its Own Playbook. Here's Why.
Arsenal Biosciences just fired 99 employees, killed its clinical programs, and bet everything on a technology that barely exists in the clinic. When a company backed by $630 million torches its own playbook, it tells you something important about where cell therapy is headed.
Imagine spending five years and over $600 million building a house, then deciding you'd rather live in a completely different neighborhood. That's essentially what Arsenal Biosciences just did.
The South San Francisco cell therapy company announced it's cutting 99 employees (the majority of its staff), halting development of its existing clinical programs, and betting the farm on an entirely different approach to cancer treatment. It's one of the most dramatic strategic pivots biotech has seen in years, and it says something important about where the smart money thinks cell therapy is headed.
From the Lab Bench to the Patient's Bloodstream
To understand why this matters, you need to know the difference between two ways of making CAR-T therapy. Think of it like cooking.
Ex vivo CAR-T (Arsenal's old approach) is like a catering operation. You take a patient's immune cells out of their body, ship them to a fancy lab, genetically engineer them to fight cancer, grow a bunch of them, run quality checks, then ship them back and infuse them into the patient. The whole process can take weeks. It costs hundreds of thousands of dollars per patient. And it requires specialized manufacturing centers that are hard to scale.
In vivo CAR-T (Arsenal's new bet) is more like a microwave meal. Instead of all that complexity, you inject a delivery vehicle directly into the patient's bloodstream. That vehicle finds the T cells already living inside the patient and reprograms them on the spot. No extraction. No factory. No weeks of waiting.
The trade-off? Ex vivo is proven. Seven CAR-T therapies are already on the market using that approach. In vivo is still experimental, with only a handful of programs in early human trials. Arsenal is essentially swapping a known quantity for a promise.
A Company That Keeps Getting Smaller
This isn't Arsenal's first round of cuts. Back in September 2025, the company went through layoffs that left it with 127 employees. Now, just a year later, it's slashing 99 more. That's a company shrinking fast.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The math is striking when you consider how much capital Arsenal has raised. An $85 million Series A in 2019. A $220 million Series B in 2022. Then a $325 million Series C in 2024, oversubscribed, that pushed the valuation to about $1.66 billion. The investor roster reads like a biotech all-star team: ARCH Venture Partners, SoftBank Vision Fund 2, Bristol-Myers Squibb, Kleiner Perkins, Regeneron Ventures, and even NVIDIA's venture arm NVentures.
All of that money funded a platform built around CRISPR-based T-cell engineering for solid tumors. Arsenal's founding team came out of the Parker Institute for Cancer Immunotherapy, combining expertise in exhausted T cells with CRISPR manipulation. The vision was compelling: crack the code on solid tumors, the holy grail of cell therapy.
Now the company is shelving those programs and looking for "strategic options" for its existing technology. Translation: they're shopping around for someone to buy or license the old stuff.
Why Burn It Down?
CEO Ken Drazan framed the pivot as building on Arsenal's core strengths in T-cell biology, synthetic biology, and computation. The company says it wants to apply those capabilities to in vivo programs and expand into hematologic malignancies and autoimmune disease, not just solid tumors.
But the real signal here isn't what Arsenal is saying. It's what they're doing. When a company fires most of its workforce and abandons clinical assets to chase a technology that's still in early trials, that's management telling you (with their actions, not their press releases) that they believe the old approach has a ceiling.
And they're not alone in that belief.
The In Vivo Gold Rush
The in vivo CAR-T space has exploded. Assets in the field grew more than tenfold from 2020 to 2024, with global funding exceeding $2 billion. By early 2025, more than five in vivo CAR programs had entered clinical trials, though about 75% of disclosed assets were still preclinical.
Big pharma has been writing enormous checks to get in. AbbVie acquired Capstan Therapeutics in 2025, gaining a Phase 1 in vivo CAR-T program targeting autoimmune disease. Kite (Gilead's cell therapy arm) bought Interius BioTherapeutics for its in vivo platform. AstraZeneca scooped up EsoBiotec. Kelonia Therapeutics started a Phase 1 study of an in vivo CAR-T for multiple myeloma in Australia. Umoja Biopharma is advancing its own platform independently.
The delivery technologies are all over the map: lipid nanoparticles, viral vectors, mRNA, circular RNA, polymers. Nobody knows which approach will win. But the consensus direction is clear: the industry is moving toward treating patients with an injection rather than a manufacturing process.
The Uncomfortable Questions
Arsenal's pivot raises several issues that don't have clean answers yet.
First, what happens to the Bristol-Myers Squibb partnership? BMS has been an investor and collaborator, and presumably had interest in Arsenal's ex vivo platform. Industry reports note the status of that relationship is unclear after the shift.
Second, can Arsenal actually compete? The in vivo field already has well-funded players with clinical data and, in several cases, big pharma backing. Arsenal is entering the race later, smaller, and after burning through significant capital on a different strategy.
Third, there's the human cost. Two rounds of major layoffs in 12 months means real people losing real jobs. The pivot may be strategically rational, but it's worth acknowledging the wreckage left behind.
What This Tells Us About the Future
Zoom out and Arsenal's move is less about one company and more about a tectonic shift in cell therapy. The current generation of CAR-T treatments works miracles for some blood cancer patients. But the manufacturing model is brutal: expensive, slow, hard to scale, and dependent on each patient's individual cells cooperating.
In vivo CAR-T promises to turn a bespoke, patient-by-patient manufacturing operation into something closer to an off-the-shelf drug. If it works, it could slash costs from hundreds of thousands of dollars to potentially tens of thousands. It could eliminate weeks of wait time. It could make cell therapy available at community hospitals, not just major academic centers.
That's a massive "if." The technology is still young. Safety questions around off-target effects and delivery precision remain unresolved. Clinical data is sparse.
But when insiders who have spent years and hundreds of millions on one approach decide to tear it all up and start over, it's worth paying attention. Arsenal Biosciences isn't just changing its strategy. It's placing a very public, very expensive bet on what cell therapy looks like in five years.
The rest of the industry is watching to see if they're visionaries or cautionary tales. Probably both.
Clinical & Regulatory
4 min read
Novo's Weight-Loss Pill Just Landed in Europe. Now the Real Test Begins.
Novo Nordisk just started selling a weight-loss pill in Germany that works about as well as the Wegovy injection. The catch? German insurance won't cover it, so patients are footing the entire bill. This is the real-world experiment that could define the future of the oral GLP-1 market.
